1. Home
  2. NCNA vs IMRN Comparison

NCNA vs IMRN Comparison

Compare NCNA & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NuCana plc

NCNA

NuCana plc

HOLD

Current Price

$1.90

Market Cap

8.8M

Sector

Health Care

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$0.80

Market Cap

7.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCNA
IMRN
Founded
1997
1994
Country
United Kingdom
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.8M
7.8M
IPO Year
2017
2016

Fundamental Metrics

Financial Performance
Metric
NCNA
IMRN
Price
$1.90
$0.80
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
25.0K
28.2K
Earning Date
06-01-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.03
$0.68
52 Week High
$10.00
$2.38

Technical Indicators

Market Signals
Indicator
NCNA
IMRN
Relative Strength Index (RSI) 43.97 54.82
Support Level $1.33 $0.69
Resistance Level $2.27 $0.89
Average True Range (ATR) 0.15 0.07
MACD -0.02 -0.00
Stochastic Oscillator 26.09 53.37

Price Performance

Historical Comparison
NCNA
IMRN

About NCNA NuCana plc

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: